EA200000897A1 - КОМПОЗИЦИЯ И СПОСОБ ПРИГОТОВЛЕНИЯ ФАРМАЦЕВТИЧЕСКОГО СОСТАВА, ЛИОФИЛИЗИРОВАННАЯ КОПОЗИЦИЯ(ВАРИАНТЫ), СПОСОБ ИНГИБИРОВАНИЯ sPLA2-ОПОСРЕДОВАННОГО ВЫСВОБОЖДЕНИЯ ЖИРНОЙ КИСЛОТЫ, СПОСОБ ЛЕЧЕНИЯ МЛЕКОПИТАЮЩИХ, СПОСОБ ЛЕЧЕНИЯ ИЛИ ПРОФИЛАКТИКИ СЕПСИСА, ЗАКРЫТАЯ ЕМКОСТЬ - Google Patents

КОМПОЗИЦИЯ И СПОСОБ ПРИГОТОВЛЕНИЯ ФАРМАЦЕВТИЧЕСКОГО СОСТАВА, ЛИОФИЛИЗИРОВАННАЯ КОПОЗИЦИЯ(ВАРИАНТЫ), СПОСОБ ИНГИБИРОВАНИЯ sPLA2-ОПОСРЕДОВАННОГО ВЫСВОБОЖДЕНИЯ ЖИРНОЙ КИСЛОТЫ, СПОСОБ ЛЕЧЕНИЯ МЛЕКОПИТАЮЩИХ, СПОСОБ ЛЕЧЕНИЯ ИЛИ ПРОФИЛАКТИКИ СЕПСИСА, ЗАКРЫТАЯ ЕМКОСТЬ

Info

Publication number
EA200000897A1
EA200000897A1 EA200000897A EA200000897A EA200000897A1 EA 200000897 A1 EA200000897 A1 EA 200000897A1 EA 200000897 A EA200000897 A EA 200000897A EA 200000897 A EA200000897 A EA 200000897A EA 200000897 A1 EA200000897 A1 EA 200000897A1
Authority
EA
Eurasian Patent Office
Prior art keywords
compositional
development
dioxoethyl
solubilizer
phenylmethyl
Prior art date
Application number
EA200000897A
Other languages
English (en)
Other versions
EA003864B1 (ru
Inventor
Уильям Лестер Конфер
Хидеаки Тай
Original Assignee
ШИОНОГИ энд КО.,ЛТД.
ИЛАЙ ЛИЛЛИ энд КО.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ШИОНОГИ энд КО.,ЛТД., ИЛАЙ ЛИЛЛИ энд КО. filed Critical ШИОНОГИ энд КО.,ЛТД.
Publication of EA200000897A1 publication Critical patent/EA200000897A1/ru
Publication of EA003864B1 publication Critical patent/EA003864B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Otolaryngology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Описана лиофилизированная фармацевтическая композиция, содержащая [[3-(2-амино-1,2-диоксоэтил)-2-этил-1-(фенилметил)-1Н-индол-4-ил]окси]ацетат натрия, солюбилизатор и стабилизатор. Такие композиции устойчивы при хранении и быстро растворяются в водной среде с образованием растворов для инъекций при лечении сепсиса и т.п.Международная заявка была опубликована вместе с отчетом о международном поиске.
EA200000897A 1998-03-03 1999-03-02 КОМПОЗИЦИЯ И СПОСОБ ПРИГОТОВЛЕНИЯ ФАРМАЦЕВТИЧЕСКОГО СОСТАВА, ЛИОФИЛИЗИРОВАННАЯ КОМПОЗИЦИЯ И ЕЕ ПРИМЕНЕНИЕ, СПОСОБ ИНГИБИРОВАНИЯ sPLA2-ОПОСРЕДОВАННОГО ВЫСВОБОЖДЕНИЯ ЖИРНОЙ КИСЛОТЫ, СПОСОБ ЛЕЧЕНИЯ МЛЕКОПИТАЮЩИХ, СПОСОБ ЛЕЧЕНИЯ ИЛИ ПРОФИЛАКТИКИ СЕПСИСА, ЗАКРЫТАЯ ЕМКОСТЬ EA003864B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7665998P 1998-03-03 1998-03-03
PCT/US1999/004516 WO1999044604A1 (en) 1998-03-03 1999-03-02 Pharmaceutical compositions containing the phospholipase inhibitor sodium [[3-(2-amino-1,2-dioxoethyl)-2-ethyl-1-phenylmethyl)-1h-indol-4-yl]oxy]acetate

Publications (2)

Publication Number Publication Date
EA200000897A1 true EA200000897A1 (ru) 2001-02-26
EA003864B1 EA003864B1 (ru) 2003-10-30

Family

ID=22133426

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200000897A EA003864B1 (ru) 1998-03-03 1999-03-02 КОМПОЗИЦИЯ И СПОСОБ ПРИГОТОВЛЕНИЯ ФАРМАЦЕВТИЧЕСКОГО СОСТАВА, ЛИОФИЛИЗИРОВАННАЯ КОМПОЗИЦИЯ И ЕЕ ПРИМЕНЕНИЕ, СПОСОБ ИНГИБИРОВАНИЯ sPLA2-ОПОСРЕДОВАННОГО ВЫСВОБОЖДЕНИЯ ЖИРНОЙ КИСЛОТЫ, СПОСОБ ЛЕЧЕНИЯ МЛЕКОПИТАЮЩИХ, СПОСОБ ЛЕЧЕНИЯ ИЛИ ПРОФИЛАКТИКИ СЕПСИСА, ЗАКРЫТАЯ ЕМКОСТЬ

Country Status (21)

Country Link
US (1) US6166062A (ru)
EP (1) EP1058547B1 (ru)
JP (3) JP2002505282A (ru)
KR (1) KR20010034552A (ru)
CN (1) CN1299277A (ru)
AT (1) ATE310513T1 (ru)
AU (1) AU757002B2 (ru)
BR (1) BR9908479A (ru)
CA (1) CA2322796A1 (ru)
DE (1) DE69928500T2 (ru)
EA (1) EA003864B1 (ru)
ES (1) ES2253877T3 (ru)
HU (1) HUP0102812A3 (ru)
ID (1) ID27487A (ru)
IL (1) IL138154A0 (ru)
NO (1) NO20004306L (ru)
NZ (1) NZ506578A (ru)
PL (1) PL342822A1 (ru)
TR (1) TR200002543T2 (ru)
TW (1) TW570795B (ru)
WO (1) WO1999044604A1 (ru)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001236440A1 (en) * 2000-01-25 2001-08-07 Eli Lilly And Company Method for the treatment of inflammation with spla2 inhibitors
JP2003525901A (ja) * 2000-03-09 2003-09-02 イーライ・リリー・アンド・カンパニー ｓＰＬＡ２インヒビターによる腎臓機能障害の治療方法
WO2002005796A2 (en) * 2000-07-14 2002-01-24 Eli Lilly And Company Use of a spla2 inhibitor for the treatment of sepsis
TWI232102B (en) 2001-07-17 2005-05-11 Shionogi & Co A pharmaceutical formulation for injection
CN1568999A (zh) * 2003-07-14 2005-01-26 南宁枫叶药业有限公司 稳定的医药用河豚毒素冷冻干燥制剂
MXPA06012777A (es) * 2004-05-06 2007-02-14 Cydex Inc Formulaciones de sabor enmascarado que contienen sertralina y eter sulfoalquilico-ciclodextrina.
TWI520735B (zh) * 2006-06-09 2016-02-11 史華茲製藥公司 含菲索特羅定之安定化醫藥組成物
RU2009134128A (ru) * 2007-02-12 2011-03-20 Лассаад БУЖБЕЛЬ (TN) Сукралоза в стерильном растворе без консервантов
JP5174365B2 (ja) * 2007-03-23 2013-04-03 第一三共株式会社 キノロン含有凍結乾燥製剤の製造方法
EP2106788A1 (en) * 2008-04-04 2009-10-07 Ipsen Pharma Liquid and freeze dried formulations
EP3563842A1 (en) 2009-04-29 2019-11-06 Amarin Pharmaceuticals Ireland Limited Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
KR20140053952A (ko) * 2011-08-26 2014-05-08 제이더블유중외제약 주식회사 피라지노-트리아진 유도체를 포함하는 조성물
EP2923710A1 (en) 2014-03-27 2015-09-30 Universitätsklinikum Heidelberg Bacterial phospholipase inhibitors as modulator of colonic bacterial flora

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO873860L (no) * 1986-10-31 1988-05-02 Asta Pharma Ag Ifosfamid-lyofilisat og fremgangsmaate til deres fremstilling.
JPH02207092A (ja) * 1989-02-07 1990-08-16 Kirin Brewery Co Ltd アンスラサイクリン化合物またはその塩の凍結乾燥製剤の製造法
JP3999263B2 (ja) * 1993-10-27 2007-10-31 ファルマシア・アンド・アップジョン・カンパニー 安定化したプロスタグランジンｅ▲１▼
AU688458B2 (en) * 1994-04-01 1998-03-12 Eli Lilly And Company 1H-indole-3-glyoxylamide sPLA2 inhibitors

Also Published As

Publication number Publication date
JP2006096761A (ja) 2006-04-13
NZ506578A (en) 2003-09-26
JP2011021042A (ja) 2011-02-03
DE69928500T2 (de) 2006-08-03
ID27487A (id) 2001-04-12
AU757002B2 (en) 2003-01-30
WO1999044604A9 (en) 2000-01-20
IL138154A0 (en) 2001-10-31
BR9908479A (pt) 2000-12-05
EP1058547A1 (en) 2000-12-13
KR20010034552A (ko) 2001-04-25
CN1299277A (zh) 2001-06-13
ES2253877T3 (es) 2006-06-01
JP2002505282A (ja) 2002-02-19
TW570795B (en) 2004-01-11
EA003864B1 (ru) 2003-10-30
NO20004306D0 (no) 2000-08-29
HUP0102812A2 (hu) 2001-12-28
US6166062A (en) 2000-12-26
EP1058547B1 (en) 2005-11-23
AU2799899A (en) 1999-09-20
PL342822A1 (en) 2001-07-02
DE69928500D1 (de) 2005-12-29
NO20004306L (no) 2000-10-10
CA2322796A1 (en) 1999-09-10
HUP0102812A3 (en) 2002-01-28
TR200002543T2 (tr) 2000-11-21
WO1999044604A1 (en) 1999-09-10
ATE310513T1 (de) 2005-12-15

Similar Documents

Publication Publication Date Title
EA200000897A1 (ru) КОМПОЗИЦИЯ И СПОСОБ ПРИГОТОВЛЕНИЯ ФАРМАЦЕВТИЧЕСКОГО СОСТАВА, ЛИОФИЛИЗИРОВАННАЯ КОПОЗИЦИЯ(ВАРИАНТЫ), СПОСОБ ИНГИБИРОВАНИЯ sPLA2-ОПОСРЕДОВАННОГО ВЫСВОБОЖДЕНИЯ ЖИРНОЙ КИСЛОТЫ, СПОСОБ ЛЕЧЕНИЯ МЛЕКОПИТАЮЩИХ, СПОСОБ ЛЕЧЕНИЯ ИЛИ ПРОФИЛАКТИКИ СЕПСИСА, ЗАКРЫТАЯ ЕМКОСТЬ
ATE345810T1 (de) Stabilisierte flüssige pharmazeutische zusammensetzung enthaltend polypeptide
KR890004718A (ko) 안정한 인체 단백질의 제조
EA200100300A1 (ru) Сухой порошок, содержащий действующее вещество, и способ доставки в легкие пациента действующего вещества
DE60233137D1 (de) Transporter mit beabstandeten arginin-teilchen
RU2008137634A (ru) Способ уменьшения агрегации белка
AR040527A1 (es) Formulaciones de hgh en alta concentracion que contienen glicina
ATE259656T1 (de) Immunoglobulin enthaltende zusammensetzung
SE0102843L (sv) Stabiliserad oral farmaceutisk komposition innehållande jodid och jodat och metod
FR2591485A1 (fr) Compositions stabilisees contenant l'activateur du plasminogene du tissu humain.
EA200001193A1 (ru) 2-фенил-1-[4-(2-аминоэтокси)бензил]индол в комбинации с эстрогенами
CY1114499T1 (el) Βιοδιαθεσιμες στερεες δοσολογικες μορφες μεταξαλονης
DK0889733T3 (da) Stabiliseret væksthormonformulering og fremgangsmåde til fremstilling deraf
DE602004015725D1 (de) Stabilisierte lyophilisierte zubereitungen mit gewebefaktor-inhibitor (tfpi) oder varianten des gewebefaktor-inhibitors
AR039123A1 (es) Composicion farmaceutica estable que contiene el factor viii
RU2005112202A (ru) Депо-препараты арилгетероциклических активных веществ в виде суспензии
EA200300406A1 (ru) Фармацевтическая композиция дронедарона для парентерального введения
KR970061246A (ko) 테스토스테론을 증가시키기 위한 약학 조성물
ES2028917T3 (es) Un procedimiento para preparar una composicion farmaceutica inyectable estable.
DE69531736D1 (de) Oxytetracyclin enthaltendes arzneimittel mit verzögerter wirksoffabgabe
PE22995A1 (es) Composicion de tiotepa liofilizada estable
JP2708749B2 (ja) 修飾型ｔＰＡ含有注射用組成物
KR840002657A (ko) 인터페론 조성물의 제조방법
EA200300234A1 (ru) Тартратные соли производного тиазолидиндиона
EA200300345A1 (ru) Гидрохлоридная соль 5-[4-[2-(n-метил-n-(2-пиридил)амино)этокси]бензил]тиазолидин-2,4-диона

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU